1. Home
  2. YSXT vs MNOV Comparison

YSXT vs MNOV Comparison

Compare YSXT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo YSX Tech. Co. Ltd Class A Ordinary Shares

YSXT

YSX Tech. Co. Ltd Class A Ordinary Shares

HOLD

Current Price

$1.35

Market Cap

27.7M

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$3.29

Market Cap

70.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSXT
MNOV
Founded
2011
2000
Country
China
United States
Employees
N/A
N/A
Industry
Automotive Aftermarket
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
70.4M
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
YSXT
MNOV
Price
$1.35
$3.29
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
33.4K
434.2K
Earning Date
02-03-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$180.00
P/E Ratio
$5.57
N/A
Revenue Growth
N/A
194.15
52 Week Low
$0.50
$1.17
52 Week High
$3.22
$3.90

Technical Indicators

Market Signals
Indicator
YSXT
MNOV
Relative Strength Index (RSI) 64.69 94.58
Support Level $0.98 $1.28
Resistance Level $1.51 N/A
Average True Range (ATR) 0.11 0.23
MACD 0.01 0.20
Stochastic Oscillator 76.78 86.50

Price Performance

Historical Comparison
YSXT
MNOV

About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares

YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: